- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03721211
Imaging With [11C]Martinostat in Breast Cancer
This research study is studying a PET imaging tracer as a possible means of imaging breast cancer.
The imaging agent involved in this study is:
-[11C]Martinostat (called C-eleven-Martinostat)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Pilot Study, which is the first time investigators are examining this study imaging agent in patients who have breast cancer.
The FDA (the U.S. Food and Drug Administration) has approved [11C]Martinostat as an investigational tracer (a type of dye used to for radiographic imaging) in a select few research studies. The FDA has not approved this tracer for any use outside of research.
In this research study, the investigators are investigating the use of a PET tracer called [11C]Martinostat in patients with breast cancer.
The purpose of the study is to take images that can measure the amount of a protein called histone deacetylase, or 'HDAC' in breast tumors. Proteins are molecules made from amino acids that perform activities in the cell for the body to function in a healthy way. Prior research suggests that HDAC levels or amounts can be altered in some breast tumors. The investigators are trying to develop a method of imaging the HDAC protein in breast tumors. This could help them to study protein changes that occur in some breast tumors, and potentially help guide treatment of breast tumors in the future.
In this study, the investigators will take the pictures of the participant's chest, including the breasts, using a PET/MRI scanner. The investigators will the study tracer, or dye, called [11C]Martinostat to make these detailed pictures.
[11C]Martinostat was initially developed to image the HDAC protein within the brain, because amounts or levels of HDAC can be altered in some diseases of the brain. In these previous studies of [11C]Martinostat conducted in humans, there were no adverse events (there have been no problems). While this is not the first time [11C]Martinostat has been used in humans, it is the first study in which the investigators are using this tracer to study breast cancer.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02214
- Massachusetts General Hospital Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be at least 18 years or age (required for legal consent)
- Have ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
- Have breast imaging findings from mammogram, ultrasound, or breast MRI that are highly suspicious (i.e. coded as BI RADS 5) for breast cancer.
- Have primary breast tumor that is at least 2 cm in diameter as measured in any dimension on either mammogram, ultrasound, or breast MRI
- Have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
General Exclusion Criteria
- Previously treated breast cancer
- Concurrent malignancy of any type
- Recent breast surgery (within the past 12 months) on the ipsilateral breast as the current breast tumor
- Impaired elimination (as defined as having problems with urination)
- Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan
- Participation in a research study/studies involving radiation exposure within the past 12 months
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, major kidney or liver disease, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnancy
- Currently lactating (either breast feeding or breast pumping)
- Pregnant women are excluded from this study because of the radioactivity of [11C]Martinostat and the resulting risks of teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of [11C]Martinostat, and because lactation may potentially affect the uptake of [11C]Martinostat on PET, breastfeeding women are excluded from the study.
General MR and PET Safety Exclusion Criteria:
- Electrical implants such as cardiac pacemakers or perfusion pumps
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing
- Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
- Inability to lie comfortably on a bed inside a PET camera for 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)
- Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure for female subjects of child-bearing age.
- Body weight of > 250 lbs (weight limit of the MRI table as well as risks to larger patients from MRI elements)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [11C]Martinostat
|
a type of dye used for radiographic imaging of the HDAC protein
Other Names:
PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PET-MRI Visualization and Quantification of Breast Tumor Uptake of [11C]Martinostat Above Background Uptake, as Assessed by SUV Measurements
Time Frame: up to 2 years
|
Evaluate the ability of PET-MRI to visualize and quantify uptake of [11C]Martinostat in breast tumors above background tracer uptake.
SUVmax will be collected from the primary breast tumor and the normal background breast tissue.
The study is powered to detect a difference in mean background SUVmax of 0.4 in breast parenchyma uninvolved by tumor and breast parenchyma with breast tumor using a two-sample t-test.
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative [11C]Martinostat-PET Uptake in Primary Breast Cancer, and Correlation with Expression of HDAC Isoforms
Time Frame: up to 2 years
|
Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis.
SUV measurements will be collected from the primary breast tumors on PET-MRI.
|
up to 2 years
|
Correlation of Total Volume of Distribution of Dynamic [11C]Martinostat Uptake with Expression of HDAC Isoforms
Time Frame: up to 2 years
|
Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis.
The total volume of [11C]Martinostat distribution will be collected from each PET-MRI.
|
up to 2 years
|
Comparison of HDAC Isoform Expression by Western Blot Across Breast Tumor Subtypes
Time Frame: up to 2 years
|
Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis and will be analyzed for an association with the tumor subtype as determined by expression of the estrogen receptor, progesterone receptor, and HER2 receptor on clinical pathology.
|
up to 2 years
|
HDAC Expression Levels in Breast Tumors Compared to HDAC Expression in Adjacent Normal Breast Parenchyma
Time Frame: up to 2 years
|
Comparison of the expression of HDAC in breast tumors to the expression of HDAC in the adjacent normal breast parenchyma.
Expression levels of HDAC isoforms will be determined from the baseline breast tumor biopsy specimens via western blot analysis.
Expression of HDAC isoforms in the normal breast parenchyma will be determined from biopsy tissue that is collected from the same breast with the cancer, but in a region of healthy breast parenchyma not involved by tumor.
|
up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Christine E Edmond, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-447
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on [11C]Martinostat
-
Massachusetts General HospitalRecruitingDiabetes | Aortic Valve Stenosis | Heart Failure With Normal Ejection Fraction | Left Ventricular HypertrophyUnited States
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
National Institute of Mental Health (NIMH)TerminatedDementiaUnited States
-
Wendell Yap, MDUniversity of Kansas Medical CenterNo longer availableProstate CancerUnited States
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Columbia UniversityCompleted
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States
-
Universitaire Ziekenhuizen KU LeuvenCHDI Foundation, Inc.Completed
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting